Press Releases

DAY HI:
DAY LOW:
VOLUME:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

Date Title Format
May 27, 2020
HENDERSON, Nev. --(BUSINESS WIRE)--May 27, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at
May 07, 2020
BLA for ROLONTIS ® (eflapegrastim) under active FDA review - PDUFA date on October 24, 2020 ROLONTIS same day dosing study initiated Updated Poziotinib strategy implemented to include new dosing regimens Poziotinib ZENITH20 Cohort 3 fully enrolled Management to host webcast and conference call
May 01, 2020
HENDERSON, Nev. --(BUSINESS WIRE)--May 1, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the first quarter 2020 financial results and provide a corporate update
Apr 30, 2020
HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 30, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced dosing of the first patient in a clinical trial to evaluate the administration of ROLONTIS on the same day as
Apr 28, 2020
ZENITH20 Phase 2 clinical trial amended to include new dosing regimens aimed at improving therapeutic index Management to host webcast and conference call today to review data and program strategy at 8:30 a.m. ET HENDERSON, Nev. --(BUSINESS WIRE)--Apr.
Apr 23, 2020
HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 23, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Seth H.Z. Fischer to its Board of Directors. Mr. Fischer fills a vacancy left by Mr.
Apr 21, 2020
Management to host webcast and conference call to review data and program strategy at 8:30 a.m. ET on April 28, 2020 HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 21, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today
Mar 17, 2020
Conference call to discuss the data and strategy for the program originally scheduled for 8 a.m. ET on March 18, 2020 has been postponed HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today
Mar 11, 2020
Management to host webcast and conference call to review data and program strategy at 8 a.m. ET on March 18, 2020 HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the
Mar 03, 2020
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at the Barclays
Feb 27, 2020
BLA for ROLONTIS ® (eflapegrastim) accepted for FDA review - PDUFA date on October 24, 2020 Data from poziotinib Cohort 1 of ZENITH20 accepted for podium presentation on March 18 at 11 th Annual Congress on Pulmonary and Respiratory Medicine in Amsterdam Spectrum plans to hold a conference call
Feb 20, 2020
HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 20, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today it will host a conference call with management to discuss the fourth quarter and full year 2019 financial
Feb 06, 2020
HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 6, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that an overview of the company's business strategy and development-stage programs will be given at the
Dec 26, 2019
HENDERSON, Nev. --(BUSINESS WIRE)--Dec. 26, 2019-- Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today reported that its pre-specified primary endpoint in its Phase 2 clinical trial evaluating poziotinib in previously
Nov 14, 2019
HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 14, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that an overview of the company's business strategy and development-stage programs will be given at the
Nov 07, 2019
Topline data from Cohort 1 of ZENITH20 trial evaluating poziotinib for NSCLC expected in December Basket trial initiated to study poziotinib in patients with EGFR or HER2 mutation-positive malignant solid tumors in an investigator-led study at The University of Texas MD Anderson Cancer Center
Oct 31, 2019
HENDERSON, Nev. --(BUSINESS WIRE)--Oct. 31, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today it will host a conference call with management to discuss the third quarter 2019 financial results, provide an
Oct 24, 2019
ROLONTIS BLA filing is based on two large pivotal randomized controlled studies that met all primary and secondary endpoints. ROLONTIS is a novel, long-acting granulocyte colony-stimulating factor (G-CSF) seeking an indication for the treatment of neutropenia in patients receiving myelosuppressive
Oct 04, 2019
  Publication highlights pre-clinical and clinical activity of poziotinib in lung cancer patients with HER2 mutations and potential future applications using monotherapy and combinations in many different mutated cancers     HENDERSON, Nev. --(BUSINESS WIRE)--Oct.
Sep 25, 2019
  HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 25, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that an overview of the company's business strategy and development-stage programs will be given at the 2019
Displaying 1 - 20 of 806